Cost & Insurance12 min readUpdated 2026-05-13

    Orforglipron Cost 2026: $1,000-$1,500/mo Expected at Launch (FDA 2027-2028)

    Orforglipron cost tracker May 2026: FDA approval projected 2027-2028, expected launch $1,000-$1,500/mo brand-name. ACHIEVE-1 Phase 3 diabetes results read out April 2026; ATTAIN-1 obesity trial late 2026. Compounded $99/mo semaglutide + $125/mo tirzepatide alternatives available now at Trimi.

    Written by Trimi Medical Team. Medically reviewed by Dr. Michael Torres, DO. This article covers orforglipron cost in 2026: what patients should know in 2026 including key considerations, treatment guidance, and practical information for patients.

    Related reading: semaglutide treatment, tirzepatide treatment, cheapest GLP-1 injections in 2026.

    What changed on April 1, 2026

    FDA approved Foundayo (orforglipron) on April 1, 2026. Because it is an oral GLP-1 option, the search intent is naturally broader than a typical approval page. Readers want to know whether an oral option is easier, cheaper, or safer enough to change their decision.

    Key Considerations

    Understanding the full picture helps you make informed decisions about your treatment journey. For additional context, explore our guides on semaglutide treatment, tirzepatide treatment, cheapest GLP-1 injections in 2026, compounded semaglutide cost and safety.

    Always consult your healthcare provider before making changes to your treatment plan

    Individual results vary based on adherence, diet, exercise, and metabolic factors

    Track your progress using both scale and non-scale indicators for the most complete picture

    Building sustainable habits alongside medication creates the strongest foundation for long-term success

    Stay informed about your treatment options and discuss any concerns with your prescribing clinician

    Frequently Asked Questions

    How much does GLP-1 medications cost per month without insurance?

    Without insurance, brand-name GLP-1 medications typically costs between $800 and $1,500 per month depending on the dose level and pharmacy. Compounded versions through licensed telehealth platforms like Trimi can significantly reduce this cost, often to $199 to $499 per month depending on the dose. Cash-pay pricing, manufacturer savings cards, and patient assistance programs can all affect your final out-of-pocket cost. The most accurate way to determine your cost is to compare branded, compounded, and insurance-covered options side by side for your specific dose.

    Does insurance cover GLP-1 medications for weight loss?

    Insurance coverage for GLP-1 medications varies significantly by plan, employer, and state. Many commercial insurance plans now cover GLP-1 medications like Wegovy or Zepbound for weight loss when patients meet specific criteria including a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or high cholesterol. However, prior authorization is almost always required, and some plans have step-therapy requirements or outright exclusions for anti-obesity medications. Contact your insurance provider directly or ask your prescribing clinician to verify coverage before starting treatment.

    What is the cheapest way to get GLP-1 medications in 2026?

    The most affordable options for GLP-1 medications in 2026 include compounded versions from licensed 503B pharmacies, which typically range from $199 to $499 per month. Other cost-reduction strategies include manufacturer savings cards that can reduce brand copays significantly, patient assistance programs for qualifying income levels, HSA or FSA funds for eligible medical expenses, and comparing cash-pay pricing across multiple pharmacies. Telehealth platforms that include prescriber visits in the medication cost can also reduce overall spending compared to separate office visit fees plus pharmacy costs.

    Are compounded versions of GLP-1 medications safe and legal?

    Compounded GLP-1 medications from FDA-registered 503A or 503B pharmacies is legal when prescribed by a licensed healthcare provider. These compounding pharmacies must follow current Good Manufacturing Practices and are subject to FDA oversight. The key safety factors to verify include whether the pharmacy holds current state and federal registrations, whether they conduct third-party potency and sterility testing, and whether the prescribing provider is board-certified. Not all compounding pharmacies maintain the same quality standards, so patients should verify credentials before starting any compounded medication.

    Can I use my HSA or FSA to pay for GLP-1 medications?

    Yes, Health Savings Accounts and Flexible Spending Accounts can generally be used to pay for GLP-1 medications when prescribed by a licensed healthcare provider for a qualifying medical condition. Weight loss medications prescribed for obesity, which is recognized as a chronic disease by the AMA and WHO, typically qualify as eligible medical expenses. This applies to both brand-name and compounded versions. Keep your prescription documentation and pharmacy receipts for tax purposes. Some HSA and FSA administrators may require a letter of medical necessity from your provider.

    What happens if my insurance denies coverage for GLP-1 medications?

    If your insurance denies coverage, you have several options. First, file a formal appeal with supporting documentation from your prescribing provider, including a letter of medical necessity that outlines your BMI, weight-related comorbidities, and prior weight loss attempts. Many initial denials are overturned on appeal. If the appeal fails, consider a compounded version through a licensed telehealth platform, which offers significant cost savings over brand pricing. You can also request that your provider submit a peer-to-peer review with the insurance medical director or explore manufacturer patient assistance programs.

    How do I compare the total cost of different GLP-1 medications providers?

    When comparing providers, look beyond the headline medication price. Total monthly cost should include the medication itself, prescriber or consultation fees, shipping or pharmacy pickup costs, required lab work or monitoring, and any membership or platform fees. Some providers bundle everything into one monthly price while others charge separately for each component. Ask specifically about costs at your target dose level, not just the starting dose, since pricing often increases with dose escalation. Also confirm refill timing policies and whether prices are locked or subject to change.

    Sources & References

    1. FDA approval announcement for Foundayo (orforglipron): fda.gov

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, adjusting, or discontinuing any medication. Individual results vary and the weight loss figures cited represent clinical trial averages, not guaranteed outcomes. GLP-1 receptor agonists require a prescription and should only be used under medical supervision.

    What does the published clinical evidence show for orforglipron?

    Peer-reviewed evidence: Once-daily oral orforglipron 45 mg produced a mean body weight reduction of approximately 14.7% at 36 weeks in adults with obesity (Phase 2) — the first non-peptide oral GLP-1 receptor agonist to reach this magnitude. (Source: Wharton et al. Phase 2 obesity trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Once-daily oral orforglipron 45 mg produced a mean body weight reduction of approximately 14.7% at 36 weeks in adults with obesity (Phase 2) — the first non-peptide oral GLP-1 receptor agonist to reach this magnitude. — Wharton et al. Phase 2 obesity trial, NEJM 2023
    Orforglipron 45 mg reduced HbA1c by approximately 2.10 percentage points at 26 weeks in patients with type 2 diabetes (Phase 2). — Frias et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Once-daily oral orforglipron 45 mg produced a mean body weight reduction of approximately 14.7% at 36 weeks in adults with obesity (Phase 2) — the first non-peptide oral GLP-1 receptor agonist to reach this magnitude. (Source: Wharton et al. Phase 2 obesity trial, NEJM 2023)
    • Orforglipron 45 mg reduced HbA1c by approximately 2.10 percentage points at 26 weeks in patients with type 2 diabetes (Phase 2). (Source: Frias et al. Phase 2 T2D trial, Lancet 2023)
    • Orforglipron is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 13, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wharton S, Blevins T, Connery L, et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2302392
    2. Frias JP, Hsia S, Eyde S, et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01303-X
    3. ClinicalTrials.gov (2024). A Study of Daily Oral Orforglipron in Adult Participants With Type 2 Diabetes (ACHIEVE-1) — NCT05869903. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Clinician-reviewed guide to tirzepatide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded tirzepatide option compares.

    A data-driven analysis of the financial and health return on investment from weight loss medication. Compare costs against savings from reduced comorbidities, fewer medications, and improved quality of life.

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Start your GLP-1 journey — from $99/mo

    Get Started